( AUSTIN Texas--(BUSINESS WIRE)--May 29...)Introgen and Clinical Collaborators to Report New Results with,Advanced-Stage Cancer Therapies at Upcoming Medical Meetings,Health

AUSTIN, Texas--(BUSINESS WIRE)--May 29, 2007 - Introgen Therapeutics, Inc. (NASDAQ:INGN) and the Company's clinical collaborators will report updated Phase 2 clinical trial results for its lead cancer therapy product candidates at the upcoming annual meetings of The American Society of Clinical Oncology (ASCO) in Chicago and the American Society of Gene Therapy (ASGT) in Seattle.

"We have a stronger than ever, advancing pipeline of first-in-class cancer therapies generating exciting data that could change the way cancer is treated and fulfill the promise of molecularly targeted cancer therapy," said Robert E. Sobol, M.D., senior vice president of Medical and Scientific Affairs at Introgen. "We have multiple Phase 3 programs either underway or planned with the goal of bringing these therapies to market to provide new treatments for widely underserved patient populations that are effective, generally well tolerated and can be easily combined and act synergistically with standard therapies by or before the end of this decade."

ASCO

-- Final results of a phase II trial of patients with extensive stage small cell lung cancer (ES-SCLC) immunized with wild type -p53 transduced dendritic cells after first-line chemotherapy, Abstract #3012: Poster presentation on Sun., June 3, from 2:00 - 6:00 p.m. in room S102a at McCormick Place, by lead author Alberto Chiappori, M.D., H. Lee Moffitt Cancer Center and Research Institute.

-- Tumor response criteria and biomarkers associated with increased survival following adenoviral p53 gene therapy (ADVEXIN) in patients with recurrent squamous cell carcinoma of the head and neck, Abstract #6057: Poster presentation on Mon., June 4, from 1:00 - 5:00 p.m. at McCormick Place by lead author John Nemunaitis, M.D., Mary Crowley Medical Research Center and poster presentation by Robert Sobol, M.D., Introgen Therapeutics, Inc.

ASGT

-- Role of the Immune Sy
'"/>

Page: 1 2 3
Related medicine technology :

1. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
2. Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors
3. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
4. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
5. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
6. Genetic Analysis Systems Enter the Clinical Mainstream
7. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
8. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
9. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society